Approval of unaudited Standalone and consolidated financial results for the Quarter ended June 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Indrayani Biotech's Q1 FY26 standalone revenue fell sharply to ₹668.57 lakhs, down from ₹1,079.09 lakhs in the same quarter last year — a drop of about 38% year-on-year. Standalone net profit was nearly flat at ₹12.77 lakhs versus ₹12.72 lakhs in Q1 FY25, with EPS of ₹0.03. On a consolidated basis, revenue declined to ₹2,910.37 lakhs from ₹3,152.78 lakhs last year (about 8% lower), while net profit dropped to ₹15.65 lakhs from ₹85.02 lakhs. The statutory auditors (Venkatesh & Co) issued an unmodified opinion on both sets of results. No exceptional items or restatements were reported.
The steep standalone revenue decline is a concern for shareholders despite profit staying positive at a thin margin. Consolidated numbers also show weaker top-line and sharply lower profit versus a year ago, suggesting softness in core operations. The clean auditor opinion is reassuring, but the weak revenue trend may weigh on the stock in the near term.